| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1996;93:870-878.)
© 1996 American Heart Association, Inc.
Articles |
Activated Partial Thromboplastin Time and Outcome After Thrombolytic Therapy for Acute Myocardial Infarction
Results From the GUSTO-I Trial
From the Department of Medicine, Duke University Medical Center, Durham, NC (C.B.G., R.M.C., L.H.W., K.L.L.); McMaster University, Hamilton, Ontario, Canada (J.H.); Clinique Universitaire St Luc, Brussels, Belgium (J.C.); Green Lane Hospital, Auckland, New Zealand (H.D.W.); Hospital Clinic I Provincial de Barcelona, Barcelona, Spain (A.B.); University of Vermont, Burlington (E.G.B.); University of Sydney, Australia (R.J.S.); and Cleveland Clinic Foundation, Cleveland, Ohio (E.J.T.).
 |
Abstract |
|---|
 Top Abstract IntroductionMethods Results Discussion References |
|---|
Background Although intravenous heparin is commonly used after thrombolytic therapy, few reports have addressed the relationship between the degree of anticoagulation and clinical outcomes. We examined the activated partial thromboplastin time (aPTT) in 29 656 patients in the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO-I) trial and analyzed the relationship between the aPTT and both baseline patient characteristics and clinical outcomes.
Methods and Results Intravenous heparin was administered as a 5000-U bolus followed by an initial infusion of 1000 U/h, with dose adjustment to achieve a target aPTT of 60 to 85 seconds. aPTTs were collected 6, 12, and 24 hours after thrombolytic administration. Higher aPTT at 24 hours was strongly related to lower patient weight (P<.00001) as well as older age, female sex, and lack of cigarette smoking (all P<.0001). At 12 hours, the aPTT associated with the lowest 30-day mortality, stroke, and bleeding rates was 50 to 70 seconds. There was an unexpected direct relationship between the aPTT and the risk of subsequent reinfarction. There was a clustering of reinfarction in the first 10 hours after discontinuation of intravenous heparin.
Conclusions Although the relationship between aPTT and clinical outcome was confounded to some degree by the influence of baseline prognostic characteristics, aPTTs higher than 70 seconds were found to be associated with higher likelihood of mortality, stroke, bleeding, and reinfarction. These findings suggest that until proven otherwise, we should consider the aPTT range of 50 to 70 seconds as optimal with intravenous heparin after thrombolytic therapy.
Key Words: anticoagulants • heparin • thrombolysis • myocardial infarction • thrombosis
|
Introduction |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
The role of intravenous heparin after thrombolytic therapy for acute myocardial infarction is ill defined. Despite the lack of definitive evidence of its effectiveness, intravenous heparin is recommended after thrombolytic therapy in the American College of Cardiology/American Heart Association guidelines.1 The anticoagulant effect of intravenous heparin usually is monitored with the activated partial thromboplastin time (aPTT).2 Data from two trials have demonstrated that aPTT values in the range of at least 45 seconds3 or at least two times control4 are associated with higher degrees of infarct-related coronary artery perfusion after administration of tissue-type plasminogen activator (TPA). However, there have been no large studies relating the degree of aPTT prolongation to clinical outcome after thrombolysis. Of note, the largest trials evaluating thrombolytic therapy-ISIS-2,5 ISIS-3,6 GISSI-1,7 and GISSI-28 -did not have the opportunity to address this issue because intravenous heparin was not used.
From 1990 to 1993, the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO-I) trial enrolled 41 021 patients with acute myocardial infarction in 15 countries in a randomized comparison of four thrombolytic treatment strategies,9 three of which included intravenous heparin. The GUSTO-I protocol called for aPTT determinations at 6, 12, and 24 hours after enrollment in patients assigned to intravenous heparin and used a standard nomogram to adjust the heparin dose. This study was intended to investigate the relationship of clinical outcomes to the aPTT response and specifically does not address whether intravenous heparin is necessary with thrombolytic therapy. We hypothesized a direct relationship of aPTT with bleeding and an inverse correlation with the end points of death and reinfarction. In addition, we investigated in this large population the relationship between key demographic factors such as weight and age and the anticoagulant effect of heparin.
|
Methods |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Patient Population
Eligibility criteria for the GUSTO-I trial have been described elsewhere.9 Briefly, patients who were within 6 hours of symptom onset of acute myocardial infarction with ECG ST-segment elevation were eligible as long as they did not have a history of stroke, active bleeding, recent major surgery, recent noncompressible vascular puncture, prior enrollment in the trial, or prior treatment with streptokinase or anistreplase.
Treatments
Qualifying patients were randomly assigned to one
of four
treatment strategies: streptokinase 1.5 million U over 60 minutes, with
subcutaneous heparin 12 500 U twice daily beginning 4 hours after the
start of thrombolytic therapy; streptokinase 1.5
million U over 60 minutes with intravenous heparin;
accelerated TPA with a bolus dose of 15 mg followed by an infusion of
0.75 mg/kg (up to 50 mg) over 30 minutes and 0.5 mg/kg (up to 35 mg)
over the next 60 minutes, with intravenous heparin; or the
combination of intravenous TPA (1.0 mg/kg over 60 minutes,
not to exceed 90 mg, with 10% given as a bolus) and streptokinase (1.0
million U over 60 minutes) with intravenous heparin. The
intravenous heparin regimen was a bolus dose of 5000 U and
then 1000 U/h for at least 48 hours, and investigators had the option
of delaying the heparin infusion (not the bolus) until the completion
of the thrombolytic therapy if there was a problem with
lack of intravenous access. In May 1992, after it was
determined that the aPTTs were below the target range in approximately
half of GUSTO-I patients at 24 hours and that the aPTTs were much more
commonly below the target range in heavier patients,10 an
informal recommendation via the project's newsletter (not a
protocol amendment) was made to increase the initial dose of
heparin to 1200 U/h for patients who weighed more than 80
kg.11
The main analyses in this study include only patients assigned to one of the three strategies with intravenous heparin who had at least one aPTT obtained.
aPTT Monitoring and Heparin Adjustment
The protocol called
for aPTT measurements at 6, 12, and 24 hours
after initiation of thrombolytic therapy in all
patients assigned to intravenous heparin. The heparin dose
was adjusted according to a nomogram (Table 1
) adapted
from Cruikshank et al,12 to achieve a target aPTT range of
60 to 85 seconds for standard aPTT reagents and median control aPTTs in
the 26- to 36-second range. If the median control aPTT fell outside
that range, a customized nomogram was developed that had a target range
of 2.0 to 2.7 times that hospital's control aPTT. This aPTT range was
intended to correspond to heparin levels in the 0.2 to 0.4 U/mL range
measured by protamine titration.2 These levels were found
to be effective in a rabbit model of jugular venous
thrombosis.13 On the basis of the 6- and 12-hour aPTTs,
the heparin dose was to be titrated upward for aPTTs less than 60
seconds. However, because the systemic fibrinogenolytic state commonly
induced by plasminogen activators is known to
cause aPTT prolongation in the early hours after
thrombolytic therapy,14 the heparin dose
was not to be titrated downward based on 6- or 12-hour aPTTs greater
than 85 seconds.
|
As an alternative to routine laboratory assessment, investigators were permitted to use the CoaguChek Plus (Boehringer Mannheim) bedside anticoagulation monitor. A nomogram was customized for that device with a target aPTT of 55 to 70 seconds, which correlates with a heparin level of 0.2 to 0.4 U/mL by protamine titration (J. Hirsh, personal communication).
The primary means of expressing aPTT in this report is in seconds rather than multiples of control. In the GUSTO-I trial, seconds were chosen as the unit of measure for aPTT because that was thought to best represent clinical practice. The control aPTT values were available from 92% of participating hospitals, so that the aPTT could be displayed either as seconds or as a multiple of control for analyses. The distribution of the controls reveals a clustering around the median of 30 seconds (25th to 75th percentile, 27 to 32 seconds), with 90% of the sites having a control aPTT in the 26- to 36-second range.
Clinical End Point Definitions
Reinfarction was defined as
"assessment by the physician that
a second myocardial infarction had occurred . . . based on the
presence of at least two of the following four criteria: recurrent
ischemic symptoms lasting >15 minutes, after resolution of
symptoms of the index infarction; occurrence of new ST-T wave changes
or new Q waves; a second elevation in cardiac enzymes to over the
normal upper limit (or by a further 20% if already over the normal
upper limit); or angiographic reocclusion of a documented previously
patent infarct-related artery."9
Moderate bleeding was defined as bleeding that required transfusion but did not lead to hemodynamic compromise requiring intervention. Severe bleeding was defined as bleeding that caused hemodynamic compromise requiring intervention. Other clinical definitions are included in the original GUSTO-I report.9
Statistical Methods
Baseline characteristics of study
patients were summarized in
terms of frequencies and percentages for categorical variables and
by the median and 25th and 75th percentiles for continuous
variables. Baseline factors associated with variability in aPTTs
were identified by univariable and multivariable
general linear regression.
The relationship of aPTT to 30-day mortality was evaluated with the use of a logistic regression model, both unadjusted and adjusted for baseline features known to be important predictors of 30-day mortality. These baseline features were identified and included in a multivariable logistic regression model previously developed and validated using the overall GUSTO-I trial population. This model has been described in detail elsewhere.15 The adjustment variables included demographics, history and risk factors, presenting characteristics, and treatment assignment.
The relationships of aPTT at 12 and 24 hours to reinfarction, cerebral infarction, intracranial hemorrhage, and moderate or severe bleeding also were evaluated with the use of logistic regression models. All of the risk modeling incorporated the use of a flexible model-fitting approach involving cubic spline functions.15 16 For reinfarction and stroke analyses, patients were excluded when the aPTTs at 12 and 24 hours were drawn after the time of onset of symptoms of reinfarction or stroke. Because the timing of bleeding was not recorded on the case report form, all aPTTs were included in the relationships with bleeding.
The comparison of primary interest in this analysis was the relationship of aPTT at 12 hours and 30-day mortality. Because of the retrospective nature of the analysis and the multiple comparisons performed, the statistical testing of other relationships should be considered to be exploratory and the significance should be interpreted with caution.
|
Results |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
The median aPTTs according to thrombolytic group assignment are summarized in Fig 1
, showing that aPTTs
were higher at 6 and 12 hours than at 24 hours (P<.0001)
and were higher in the streptokinase-treated and
intravenous heparin–treated patients in the first 12
hours after thrombolytic administration
(P<.0001). At 24 hours, nearly 50% of patients in all
treatment groups had an aPTT below the target range of 60 to 85
seconds.
|
Demographic Variables as Predictors of aPTT
The median
24-hour aPTTs according to categorical baseline
features are shown in Table 2. Women, nonsmokers,
patients without diabetes, and patients presenting in cardiogenic
shock had higher aPTTs. Fig 2 shows that patients who
were lighter-weight, older, and shorter had higher 24-hour aPTTs.
The univariable and multivariable significance of these
relationships is shown in Table 3. The major determinant
of the aPTT response to fixed doses of heparin was patient weight.
Every 10-kg increase in weight was associated on the average with a
6-second decrease in aPTT. Age and sex also were highly statistically
significant predictors of aPTT, with each 10 years of additional age
corresponding to an average increase in aPTT of 5 seconds and women
having a median aPTT 11 seconds higher than men. Cigarette smokers had
lower aPTTs than nonsmokers, even after adjustment for weight, age, and
sex. Height, systolic blood pressure, and pulse were no longer
significant predictors after adjustment for other variables.
|
|
|
Outcomes and aPTT
As expected, the higher the aPTT, the
higher the incidence of
moderate or severe bleeding (Fig 3A). The risk appeared
to increase dramatically beyond an aPTT of 60 to 70 seconds. For aPTTs
between 60 and 100 seconds, there was approximately a 1% increase in
the risk of bleeding for every 10-second increase in the 12-hour
aPTT.
|
The relationships of 12- and 24-hour aPTTs with subsequent stroke
(primary intracranial hemorrhage and cerebral infarction) are
shown in Figs 3B
and 3C. Thirty-six and 38 of
the intracranial
hemorrhages and 11 and 17 of the cerebral infarcts were removed
from analyses of 12- and 24-hour aPTTs, respectively, because
the stroke onset was before the aPTT determination. Stroke rates, both
primary hemorrhagic and nonhemorrhagic, were either similar or higher
with higher aPTTs compared with lower aPTTs at 12 hours.
The
relationships of 12- and 24-hour aPTTs with subsequent reinfarction
for patients assigned to intravenous heparin are
illustrated in Fig 3D. The median time to reinfarction onset
among the
1285 patients with reinfarction was 3.8 days. For the 12- and 24-hour
aPTT data, one and five of the reinfarctions, respectively, were
removed because the onset was before the aPTT determination. The
likelihood of subsequent reinfarction was higher for higher aPTT
values. Of the 543 patients who were assigned to
intravenous heparin and suffered reinfarction while on
intravenous heparin, the median aPTT values at 6, 12, and
24 hours were 100, 86, and 66 seconds. Of the 613 patients who were
assigned to intravenous heparin, suffered reinfarction
after intravenous heparin was discontinued, and had the
time of heparin discontinuation noted, 44% occurred within 20 hours of
stopping heparin and 33% occurred within 10 hours of stopping heparin
(Fig 4). The likelihood of reinfarction after
intravenous heparin discontinuation was highest at 2 to 4
hours after discontinuation. Of patients who had reinfarction in the
first day after heparin discontinuation, median aPTTs at 12 and 24
hours were 85 and 68 seconds, respectively.
|
Fig 5
displays the relationship of 12-hour aPTT with
30-day mortality for the 26 759 patients assigned to
intravenous heparin who had 12-hour aPTT determinations.
The lowest 30-day mortality was seen when the aPTT was in the range of
50 to 70 seconds 12 hours after thrombolytic therapy;
patients with aPTTs of 150 seconds had more than a 50% higher
mortality than those with aPTTs of 60 seconds. Because higher aPTTs are
related to both higher mortality and older age, adjustment for
mortality differences for various aPTT levels explained by differences
in baseline characteristics is important to determine the independent
relationship of aPTT with mortality. After adjustment for baseline
characteristics (Fig 5), the relationship between increasing
mortality
with aPTT greater than 70 seconds persisted (P=.01). A
similar relationship was seen when aPTT was examined as a multiple of
the control value, as expected because of the tight clustering of
control aPTTs around the 30-second range.
|
Because the relative lack of fibrinogenolysis with TPA might make higher levels of heparin anticoagulation more important for patient outcome compared with streptokinase, we also examined the relationship between aPTT and 30-day mortality in TPA-assigned patients alone. We found the same relationship with the lowest mortality in the mid-level aPTT range of 50 to 70 seconds. There was no statistical interaction (P=.17) between thrombolytic assignment and relationship of 12-hour aPTT with 30-day mortality.
Of the patients in this analysis, 515 and 626 had coronary angioplasty prior to the 12- and 24-hour aPTTs, respectively. The median aPTTs were 100 seconds and 61 seconds at 12 hours and 24 hours, respectively, among patients with preceding angioplasty versus 79 seconds and 62 seconds for patients without preceding angioplasty. The relationships of 12-hour aPTT with mortality and with reinfarction were reanalyzed after removing the patients undergoing angioplasty prior to 12 hours, and the findings were unchanged, with the lowest mortality at 50 to 70 seconds (P<.001) and the lowest reinfarction rate at the lowest aPTT level (P<.001).
To determine the relationship between change in aPTT over time and outcome, we determined the change in aPTT between the 12- and 24-hour time points and compared it with outcomes. The lowest mortality was seen in patients who had no substantial change in aPTT over time, and mortality was higher among patients with a significant increase or decrease in aPTT. The risk of bleeding was higher with increasing aPTT and lower with decreasing aPTT, and the risk of reinfarction was higher with increasing aPTT and not different with decreasing aPTT.
|
Discussion |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
There are three novel findings of this study, two of which are biologically plausible and therefore not unexpected, while the third is difficult to explain and unexpected. The expected findings are that the aPTT is inversely correlated with patient weight and is strongly associated with an increase in bleeding. The unexpected finding is that the rates of mortality and reinfarction are strongly and significantly associated with higher aPTT values.
Determinants of aPTT
Previous studies of pharmacokinetics of
heparin in patients with
venous thromboembolic disease have demonstrated that heparin is
eliminated more rapidly among smokers and in men and that higher doses
of heparin are required for heavier patients.17 Our study
is much larger than previous studies and therefore provides robust
estimates of the influence of factors that affect the aPTT response to
heparin in the setting of modern coronary care.
The information obtained on the 24-hour aPTT allowed us to explore patient factors that influence the anticoagulant response to intravenous heparin. The majority of these patients did not have their heparin dose adjusted in the first 24 hours because the aPTT was below 60 seconds in less than 30% of patients and because the protocol did not call for dosage adjustment when the aPTT was above 85 seconds in the first 24 hours.
The inverse relationship between patient weight and heparin effect in this study is consistent with previous experimental studies that have reported a relationship between patient weight and either aPTT18 or heparin requirements.19 This may be related to the finding that heparin distributes into plasma volume,20 which is proportional to body weight. Our patients received thrombolytic therapy, but the results are likely to be generalizable to all patients treated with heparin because most effects of thrombolytic therapy on coagulation disappear by 24 hours.14
The reason that patient characteristics of age, sex, and smoking status are important predictors of aPTT is not readily apparent; the mediators of the effect and half-life of heparin are complex.2 Clearance is thought to be largely due to metabolism by endothelial cells and macrophages21 22 as well as by the renal route.23
Association of aPTT and Bleeding
As expected, the incidence
of moderate or severe bleeding was
higher among patients with higher aPTTs. Although the incidence of
bleeding has been shown to be higher with the use of
intravenous heparin after thrombolytic
therapy24 and with higher doses of heparin,25
the relationship of degree of aPTT prolongation and bleeding risk has
been less clear. Although some studies have found a significant
relationship between higher aPTTs and higher risk of hemorrhage
among heparin-treated patients after
thrombolysis,4 26 others have
not.3 27 This may relate to the fact that patients
who
suffer bleeding complications have their heparin discontinued;
therefore, the true relationship of aPTT and bleeding risk is obscured
by a subset of patients in whom lower aPTTs are a consequence of the
bleeding complications. This is the most likely explanation for the
higher incidence of bleeding observed in this study with low aPTTs at
24 hours and the finding in the TIMI 9A trial26 of a
statistically lower incidence of bleeding with higher aPTT values at 24
hours (P=.04). The current study demonstrates that
increasing aPTT values, especially greater than 70 seconds, both in the
early hours and in the later hours after thrombolysis,
are associated with increasing risk of bleeding.
Association of aPTT and Stroke
The higher incidence of
hemorrhagic stroke with higher aPTTs is
consistent with an expected increased bleeding risk with
greater anticoagulation and with the findings of higher aPTTs among
patients who suffered intracranial hemorrhage in GUSTO
IIa.28 Moreover, certain patient
characteristics—lower weight, older age, and female sex—are
associated with both a higher rate of intracranial hemorrhage
after thrombolytic therapy29 and higher
aPTTs. There was no evidence of a lower subsequent incidence of
cerebral infarction with increasing aPTT values above 60 to 70 seconds.
Although lower levels of heparin anticoagulation, for example 12 500 U
subcutaneous twice daily,30 are known to protect against
left ventricular thrombus formation after acute myocardial
infarction, this study suggests that higher degrees of anticoagulation
may not protect against ischemic or embolic stroke after
thrombolysis.
Association of aPTT and Reinfarction
An unexpected finding
was the higher incidence of reinfarction
among patients with higher aPTT. This relationship suggests that higher
degrees of anticoagulation with heparin do not protect against
reinfarction. Similar to the finding of Theroux et al31 in
patients with unstable angina, we identified a clustering of
reinfarction events among patients who suffered reinfarction after
discontinuation of heparin, with one third occurring within 10 hours of
heparin discontinuation and nearly one half within 20 hours. The
finding that the most likely time for reinfarction is 2 to 4 hours
after stopping intravenous heparin suggests that patients
should be observed carefully in the early hours after stopping
intravenous heparin and that methods are needed to protect
patients from reinfarction during this high-risk period. Unlike the
findings of Theroux et al, in this study the clustering of events
occurred despite the universal use of aspirin. aPTTs were higher among
patients who suffered reinfarctions whether the reinfarctions occurred
during or after heparin discontinuation.
The reason that higher aPTTs were associated with a higher rate of reinfarction is unknown. Higher aPTTs may be associated with other factors that result in a higher risk of reinfarction, or reinfarction could be delayed among patients with higher aPTTs on the first day until it is more likely to be clinically recognized. Another possible explanation is that higher early aPTTs due to fibrin degradation products, fibrinogenolysis, and plasmin degradation of factors V and VIII would prompt a reduction in the heparin dose, which would expose patients to a higher subsequent risk of reinfarction. The persistence of the relationship between higher 24-hour aPTTs and the higher risk of reinfarction does not support this possibility. Finally, higher aPTTs may be associated with higher rates of earlier infarct-related artery opening, resulting in an increased opportunity for reocclusion and reinfarction.
Association of aPTT and Mortality
Because the angiographic
evidence shows that infarct-related
coronary artery patency is better with aPTTs greater than two
times control,3 4 the observed relationship between
the
aPTT and mortality in GUSTO I is unexpected. A number of patient
characteristics including lighter weight, female sex, older age, and
nonsmoking are predictors of both higher risk of death and longer aPTT
times. After adjustments are made for these and other differences in
baseline characteristics, aPTT values higher than approximately 60 to
70 seconds remain associated (P=.01) with an increase in the
risk of death.
The reasons for the higher mortality among patients with aPTT values greater than 70 seconds, even after adjustment for baseline differences, are unclear. The increased risk of serious hemorrhage, including intracranial hemorrhage, only partially explains the increased mortality with higher aPTTs. The finding that there was no apparent protection against reinfarction or recurrent ischemia with higher early aPTTs is counterintuitive. This could be explained by the greater heparin effect either not preventing thrombosis or preventing the thrombotic events during administration, with an increase in risk upon stopping the heparin. Possible prothrombotic effects of higher doses of heparin by directly promoting platelet aggregation32 or via "rebound" hypercoagulability after heparin cessation,33 possibly in part by decreasing anti–thrombin III levels,34 are called into question.
Relationship of Change in aPTT Over Time and Outcome
As
expected, a decrease in aPTT between the 12- and 24-hour time
points was associated with a lower risk of bleeding. A decrease in aPTT
over time was not associated with an increased risk of reinfarction.
This suggests that the reason for the increased risk of reinfarction
with higher aPTTs at 12 hours was not due to the high aPTTs prompting a
decrease in heparin dose with a resultant fall in the aPTT. The lowest
mortality was associated with a stable aPTT at 12 and 24 hours in the
50- to 70-second range.
Limitations
Because analyses of the 12- and 24-hour aPTTs
could
include only patients who survived long enough to have the samples
drawn and 40% of the 30-day mortality occurred within 24 hours, the
results are based on data less representative of
patients at high risk for early death. The 12- and 24-hour aPTTs were
chosen to compare with clinical outcomes because they relate more to
heparin effect than the 6-hour aPTT, which is more strongly influenced
by which thrombolytic agent was used. The relationships
between 12-hour aPTT and outcomes may be the most informative because
fewer patients are excluded because of early death, and more subsequent
events (death, reinfarction, and stroke) are available to which
correlations can be made. Whether these data relating aPTT to outcome,
obtained from only two samples per patient during the first 24 hours
after thrombolytic therapy, apply to subsequent aPTTs
is unknown.
Although mortality appears to be higher with aPTTs less than 50 seconds, the confidence intervals are wide because there are relatively few data points, and more data are needed to clearly define the relationship of aPTT to outcome in the low aPTT range. Although this analysis does show that higher aPTTs are associated with worse outcomes, the data do not specifically address how an individual practitioner should respond to a patient with a high aPTT.
The lack of standardized or normalized methods for aPTT determination is a limitation of any large multicenter study examining aPTT values because of the variation in responsiveness of the aPTT to heparin among different reagents.35 36 However, unless a standardized approach is established, any large-scale multicenter study representing a broad experience of clinical practice will be limited by the heterogeneity of aPTT determination methods.
At present, there has been no definitive large randomized trial that has shown that adjuvant therapy with intravenous heparin is beneficial in improving major clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy. However, if there is a role for intravenous heparin, then any beneficial anticoagulant effect of heparin when given to prolong the aPTT beyond approximately 70 seconds is overridden by a combination of patient-related determinants that influence both the aPTT and the mortality rate in the same direction and a possible detrimental effect of high levels of heparin anticoagulation.
Conclusions
This analysis does not provide definitive
conclusions as
to the optimal aPTT target range. The lower mortality observed among
patients with middle-level aPTTs is confounded by differences in
baseline characteristics. Even after adjustment for baseline
differences among patients with different aPTT levels, it is unclear
whether higher aPTTs are a cause or a result of worse clinical outcome.
Even so, the association is noteworthy and has not been documented
previously. To definitively address the issue of optimal aPTT range,
patients would need to be randomized to various aPTT target ranges
using a standardized aPTT determination method. Nevertheless, these
data caution against routine use of heparin to achieve aPTT levels
greater than 70 seconds and suggest that until more data are available,
an optimal range may be 50 to 70 seconds, or approximately two times
control. Although heparin anticoagulation has been used in routine
clinical practice for many years, there is need for continued
investigation to both understand and optimize its effects.
|
Acknowledgments |
|---|
This study was supported by Bayer (New York, NY), CIBA-Corning (Medfield, Mass), Genentech (South San Francisco, Calif), ICI Pharmaceuticals (Wilmington, Del), and Sanofi Pharmaceuticals (Paris, France).
|
Footnotes |
|---|
Reprint requests to Christopher B. Granger, MD, Box 3409, Duke University Medical Center, Durham, NC 27710.
Received May 22, 1995; revision received October 9, 1995; accepted October 10, 1995.
|
References |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
1. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction). J Am Coll Cardiol. 1990;16:249-292. [Medline] [Order article via Infotrieve]
2. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574. [Medline] [Order article via Infotrieve]
3. Hsia J, Kleiman NS, Aguirre FV, Chaitman BR, Roberts R, Ross AM. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. J Am Coll Cardiol. 1992;20:31-35. [Abstract]
4. Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol. 1992;20:513-519. [Abstract]
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;349-360.
6. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised trial of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770. [Medline] [Order article via Infotrieve]
7. Gruppo Italiano per lo Studio della Stretochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402. [Medline] [Order article via Infotrieve]
8. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet. 1990;336:65-71. [Medline] [Order article via Infotrieve]
9.
The GUSTO-I Investigators. An international randomized
trial comparing four thrombolytic strategies for acute
myocardial infarction. N Engl J Med. 1993;329:673-682.
10. Granger CB, Califf RM, Hirsh J, Woodlief LH, Topol EJ. APTTs after thrombolysis and standard intravenous heparin are often low and correlate with body weight, age and sex: experience from the GUSTO-I trial. Circulation. 1992;86(suppl I):I-258. Abstract.
11. GUSTO Gazette. 1992;5/6:1.
12.
Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza
M. A standard heparin nomogram for the management of heparin
therapy. Arch Intern Med. 1991;151:333-337.
13.
Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M.
Relationship between the anticoagulant and antithrombotic effects of
heparin in experimental venous thrombosis. Blood. 1977;49:171-184.
14. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML, for the TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11. [Abstract]
15.
Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col
J, Simoons M, Aylward P, van de Werf F, Califf RM, for the GUSTO-I
Investigators. Predictors of 30-day mortality in the era of reperfusion
for acute myocardial infarction: results from an international trial of
41 021 patients. Circulation. 1995;91:1659-1668.
16. Devlin TF, Weeks BJ. Spline functions for logistic regression modeling. Proc 11th Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc; 1986:646-651.
17. Cipolle R, Seifert R, Neilan B, Zaske DE, Haus E. Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther. 1981;29:387-393. [Medline] [Order article via Infotrieve]
18. Flaker G, Bartolozzi J, Davis V, McCabe C, Cannon C, for the TIMI 4 Investigators. Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. Arch Intern Med. 1994;1492-1496.
19.
Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas
S. The weight-based heparin dosing nomogram compared with a
`standard care' nomogram: a randomized controlled trial.
Ann Intern Med. 1993;119:874-881.
20. Estes JW. The fate of heparin in the body. Curr Ther Res. 1975;18:45-57.
21. Glimelius B, Busch C, Hook M. Binding of heparin on the surface of cultured human endothelial cells. Thromb Res. 1978;12:773-782. [Medline] [Order article via Infotrieve]
22. Friedman Y, Arsenis C. Studies on the heparin sulphamidase activity from rat spleen: intracellular distribution and characterization of the enzyme. Biochem J. 1974;139:699-708. [Medline] [Order article via Infotrieve]
23. Perry PT, Herin GR, King JC. Heparin half-life in normal and impaired renal function. Clin Pharmacol Ther. 1974;16:514-519. [Medline] [Order article via Infotrieve]
24. Mahaffey KW, Granger CB, O'Connor CM, Ohman EM, Bleich SD, Col J, Califf RM. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol. In press.
25. Levine MN, Hirsh J, Kelton JG. Heparin-induced bleeding. In: Lane DA, Lindahl U, eds. Heparin: Chemical and Biological Properties and Clinical Applications. London: Edward Arnold; 1989:517-532.
26. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis D, Lambrew CT, Leiboff R, Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH, for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med. 1991;115:256-265.
27.
Antman EM, for the TIMI 9A Investigators. Hirudin in
acute myocardial infarction: safety report from the
thrombolysis and thrombin inhibition in myocardial
infarction (TIMI) 9A trial. Circulation. 1994;90:1624-1630.
28.
The Global Use of Strategies to Open Occluded
Coronary Arteries (GUSTO) IIa Investigators. Randomized trial
of intravenous heparin versus recombinant hirudin for acute
coronary syndromes. Circulation. 1994;90:1631-1637.
29. Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, de Jaegere P, van Domburg R, Boersma E, Franzosi MG, Califf R, Schroder R, Braunwald E. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet. 1993;342:1523-1528. [Medline] [Order article via Infotrieve]
30. SCATI Investigators. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction: the SCATI (Studio sulla Calciparina nell'Angina e nella Trombosi Ventricolare nell'Infarto) Group. Lancet. 1989;2:182-186. [Medline] [Order article via Infotrieve]
31. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327:141-145. [Abstract]
32. Chen J, Karlberg KE, Sylven C. Heparin enhances platelet aggregation irrespective of anticoagulation with citrate or with hirudin. Thromb Res. 1992;67:253-262. [Medline] [Order article via Infotrieve]
33.
Granger CB, Miller J, Bovill EG, Gruber A, Tracy RP,
Krucoff MW, Green C, Berrios E, Harrington RA, Ohman EM, Califf
RM. Rebound increase in thrombin generation and activity after
cessation of intravenous heparin in patients with acute
coronary syndromes. Circulation. 1995;91:1929-1935.
34. Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet. 1977;2:581-584. [Medline] [Order article via Infotrieve]
35.
Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh
J. Establishing a therapeutic range for heparin therapy.
Ann Intern Med. 1993;119:104-109.
36. D'Angelo A, Seveso MP, D'Angelo SV, Gilardoni F, Dettori AG, Bonini P. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT): implications in heparin monitoring by APTT. Am J Clin Pathol. 1990;94:297-306.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  A. Kumar and C. P. Cannon Acute Coronary Syndromes: Diagnosis and Management, Part II Mayo Clin. Proc., November 1, 2009; 84(11): 1021 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cheng, D. A. Morrow, S. Sloan, E. M. Antman, and M. S. Sabatine Predictors of Initial Nontherapeutic Anticoagulation With Unfractionated Heparin in ST-Segment Elevation Myocardial Infarction Circulation, March 10, 2009; 119(9): 1195 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Eikelboom and J. I. Weitz Anticoagulation for ST-Segment Elevation Myocardial Infarction Circulation, March 10, 2009; 119(9): 1186 - 1188. [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Hamm, H. Möllmann, J.-P. Bassand, and F. van de Werf CHAPTER 16 Acute Coronary Syndromes ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: Eur. Heart J., December 1, 2008; 29(23): 2909 - 2945. [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
|
|
S. V. Rao, J. A. Eikelboom, C. B. Granger, R. A. Harrington, R. M. Califf, and J.-P. Bassand Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes Eur. Heart J., May 2, 2007; 28(10): 1193 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Dyke, S. R. Steinhubl, N. S. Kleiman, R. O. Cannon, L. G. Aberle, M. Lin, S. K. Myles, C. Melloni, R. A. Harrington, J. H. Alexander, et al. First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity Circulation, December 5, 2006; 114(23): 2490 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Nallamothu, E. R. Bates, J. S. Hochman, C. B. Granger, V. Guetta, R. G. Wilcox, H. D. White, P. W. Armstrong, S. Savonitto, G. Jia, et al. Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial Eur. Heart J., August 1, 2005; 26(15): 1506 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Andreotti and R. C. Becker Atherothrombotic Disorders: New Insights From Hematology Circulation, April 12, 2005; 111(14): 1855 - 1863. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Smythe and A. Caffee Anticoagulation Monitoring Journal of Pharmacy Practice, October 1, 2004; 17(5): 317 - 326. [Abstract] [PDF]
|
|
|
|
|
|
P. Voci, F. Pizzuto, and F. Romeo The slippery slope Eur. Heart J., September 1, 2004; 25(17): 1480 - 1482. [Full Text] [PDF]
|
|
|
|
|
|
J. Hirsh and R. Raschke Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 188S - 203S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Writing Committee Members, E. M. Antman, D. T. Anbe, P. W. Armstrong, E. R. Bates, L. A. Green, M. Hand, J. S. Hochman, H. M. Krumholz, F. G. Kushner, et al. ACC/AHA guidelines for the management of patients with ST-Elevation myocardial infarction--executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction) J. Am. Coll. Cardiol., August 4, 2004; 44(3): 671 - 719. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman, D. T. Anbe, P. W. Armstrong, E. R. Bates, L. A. Green, M. Hand, J. S. Hochman, H. M. Krumholz, F. G. Kushner, G. A. Lamas, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Circulation, August 3, 2004; 110(5): 588 - 636. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Trouillas, L. Derex, F. Philippeau, N. Nighoghossian, J. Honnorat, M. Hanss, P. Ffrench, P. Adeleine, and M. Dechavanne Early Fibrinogen Degradation Coagulopathy Is Predictive of Parenchymal Hematomas in Cerebral rt-PA Thrombolysis: A Study of 157 Cases Stroke, June 1, 2004; 35(6): 1323 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A Brouwer, N Clappers, and F W A Verheugt Adjunctive treatment in patients treated with thrombolytic therapy Heart, May 1, 2004; 90(5): 581 - 588. [Full Text] [PDF]
|
|
|
|
|
|
N. R. Bijsterveld, R. J. G. Peters, S. A. Murphy, P. J. L. M. Bernink, J. G. P. Tijssen, M. Cohen, and TIMI 11B/ESSENCE Study Groups Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: Results from the thrombolysis in myocardial infarction (TIMI) 11B and efficacy and safety of subcutaneous enoxaparin in Non-Q-Wave coronary events (ESSENCE) studies J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2083 - 2089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Moliterno, J. B. Hermiller, D. J. Kereiakes, E. Yow, R. J. Applegate, G. A. Braden, E. J. Dippel, M. I. Furman, C. L. Grines, N. S. Kleiman, et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention: Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1132 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Anand, S. Yusuf, J. Pogue, J. S. Ginsberg, and J. Hirsh Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin Circulation, June 17, 2003; 107(23): 2884 - 2888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Goodman, D. Fitchett, P. W. Armstrong, M. Tan, A. Langer, and for the Integrilin and Enoxaparin Randomized Asses Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide Circulation, January 21, 2003; 107(2): 238 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Task Force on the Management of Acute Myocardi, F. Van de Werf, D. Ardissino, A. Betriu, D. V. Cokkinos, E. Falk, K. A.A. Fox, D. Julian, M. Lengyel, F.-J. Neumann, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation Eur. Heart J., January 1, 2003; 24(1): 28 - 66. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Brouwer, P. J.P.C. van den Bergh, W. R.M. Aengevaeren, G. Veen, H. E. Luijten, D. P. Hertzberger, A. J. van Boven, R. P.J.W. Vromans, G. J.H. Uijen, and F. W.A. Verheugt Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial Circulation, August 6, 2002; 106(6): 659 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kottke-Marchant, M.C. Bahit, C.B. Granger, P. Zoldhelyi, D. Ardissino, L. Brooks, J.H. Griffin, R.F. Potthoff, F. Van de Werf, R.M. Califf, et al. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes Eur. Heart J., August 1, 2002; 23(15): 1202 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.J. Van de Werf, E.M. Antman, and M.L. Simoons Managing ST elevation myocardial infarction Eur. Heart J. Suppl., May 1, 2002; 4(suppl_E): E15 - E23. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Luciardi, S. Berman, J. Muntaner, F. De La Serna, and R. Altman Facilitated Thrombolysis: Dethrombosis? Clinical and Applied Thrombosis/Hemostasis, April 1, 2002; 8(2): 133 - 138. [Abstract] [PDF]
|
|
|
|
|
|
J M Estess and E J Topol Fibrinolytic treatment for elderly patients with acute myocardial infarction Heart, April 1, 2002; 87(4): 308 - 311. [Full Text] [PDF]
|
|
|
|
|
|
N. R. Bijsterveld, A. H. Moons, J. C. M. Meijers, J. G. P. Tijssen, H. R. Buller, M. Levi, and R. J. G. Peters Rebound thrombin generation after heparin therapy in unstable angina: A randomized comparison between unfractionated and low-molecular-weight heparin J. Am. Coll. Cardiol., March 6, 2002; 39(5): 811 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Randomized, Placebo-Controlled Trial of Titrated Intravenous Lamifiban for Acute Coronary Syndromes Circulation, January 22, 2002; 105(3): 316 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Lauer, P. L. Houghtaling, J. G. Peterson, C. B. Granger, D. L. Bhatt, S. K. Sapp, M. L. Simoons, R. A. Harrington, E. J. Topol, and A. M. Lincoff Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary Syndromes: Observations From the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Circulation, December 4, 2001; 104(23): 2772 - 2777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Hudson, C. B. Granger, E. J. Topol, K. S. Pieper, P. W. Armstrong, G. I. Barbash, A. D. Guerci, A. Vahanian, R. M. Califf, and E. M. Ohman Early Reinfarction After Fibrinolysis: Experience From the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO III) Trials Circulation, September 11, 2001; 104(11): 1229 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.S. Alpert, A.J. Budaj, E.P. Gurfinkel, and T.D. Henry Issues in antithrombin therapy for UA/NSTEMI Eur. Heart J. Suppl., August 1, 2001; 3(suppl_J): J15 - J23. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Llevadot, R. P. Giugliano, and E. M. Antman Bolus Fibrinolytic Therapy in Acute Myocardial Infarction JAMA, July 25, 2001; 286(4): 442 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Akkerhuis, J. W. Deckers, A. M. Lincoff, J. E. Tcheng, E. Boersma, K. Anderson, C. Balog, R. M. Califf, E. J. Topol, and M. L. Simoons Risk of Stroke Associated With Abciximab Among Patients Undergoing Percutaneous Coronary Intervention JAMA, July 4, 2001; 286(1): 78 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lopez-Sendon Coronary reperfusion in the clinical setting: antithrombotic support to thrombolysis in the coronary care unit Eur. Heart J. Suppl., June 1, 2001; 3(suppl_C): C55 - C61. [Abstract] [PDF]
|
|
|
|
|
|
M. C. Bahit, E. J. Topol, R. M. Califf, P. W. Armstrong, D. A. Criger, V. Hasselblad, A. Betriu, J. Hirsh, D. Ardissino, and C. B. Granger Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb J. Am. Coll. Cardiol., March 15, 2001; 37(4): 1001 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Armstrong, C. Granger, and F. Van de Werf Bolus Fibrinolysis : Risk, Benefit, and Opportunities Circulation, February 27, 2001; 103(8): 1171 - 1173. [Full Text] [PDF]
|
|
|
|
|
|
D. P. Chew, D. L. Bhatt, A. M. Lincoff, D. J. Moliterno, S. J. Brener, K. E. Wolski, and E. J. Topol Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention : Aggregate Results From 6 Randomized, Controlled Trials Circulation, February 20, 2001; 103(7): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V Menon, J.S Hochman, A Stebbins, M Pfisterer, J Col, R.D Anderson, D Hasdai, D.R Holmes Jr, E.R Bates, E.J Topol, et al. Lack of progress in cardiogenic shock: lessons from the GUSTO trials Eur. Heart J., December 1, 2000; 21(23): 1928 - 1936. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Manhapra and S. Borzak Regular review: Treatment possibilities for unstable angina BMJ, November 18, 2000; 321(7271): 1269 - 1275. [Full Text]
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes JAMA, September 27, 2000; 284(12): 1549 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) J. Am. Coll. Cardiol., September 1, 2000; 36(3): 970 - 1062. [Full Text] [PDF]
|
|
|
|
|
|
L. Cho, E. J. Topol, C. Balog, J. M. Foody, J. E. Booth, C. Cabot, N. S. Kleiman, J. E. Tcheng, R. Califf, and A. M. Lincoff Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: Pooled analysis from EPIC, EPILOG and EPISTENT trials J. Am. Coll. Cardiol., August 1, 2000; 36(2): 381 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.A. Harrington and M.L. Simoons What have we learned from the recent large trials in acute coronary syndromes without ST-segment elevation? Eur. Heart J., May 1, 2000; 21(9): 702 - 704. [PDF]
|
|
|
|
|
|
J. Oldgren, R. Linder, L. Grip, A. Siegbahn, and L. Wallentin Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease Eur. Heart J., November 2, 1999; 20(22): 1657 - 1666. [Abstract] [PDF]
|
|
|
|
|
|
G. Frostfeldt, G. Ahlberg, G. Gustafsson, G. Helmius, B. Lindahl, A. Nygren, A. Siegbahn, E. Swahn, P. Venge, and L. Wallentin Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction--a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II) J. Am. Coll. Cardiol., March 1, 1999; 33(3): 627 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon, J. Dingemanse, C. H. Kleinbloesem, T. Jannett, K. M. Curry, and C. P. Valcke Automated Heparin-Delivery System to Control Activated Partial Thromboplastin Time : Evaluation in Normal Volunteers Circulation, February 16, 1999; 99(6): 751 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Becker, J. S. Hochman, C. P. Cannon, F. A. Spencer, S. P. Ball, M. J. Rizzo, E. M. Antman, and for the TIMI 9 Investigators Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: Observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study J. Am. Coll. Cardiol., February 1, 1999; 33(2): 479 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S A J Chamuleau, R J de Winter, M Levi, R Adams, H R Büller, M H Prins, K I Lie, and R J G Peters Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study Heart, July 1, 1998; 80(1): 35 - 39. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Mungall, B. A. Baker, and M. D. Adelman Activated Partial Thromboplastin Time vs Heparin Concentration Arch Intern Med, June 8, 1998; 158(11): 1273 - 1275. [Full Text] [PDF]
|
|
|
|
 |
|
 The Platelet Receptor Inhibition in Ischemic Syndr A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina N. Engl. J. Med., May 21, 1998; 338(21): 1498 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Frei, J. Brophy, F. Andreotti, C. D. Thron, E. J. Topol, R. M. Califf, R. Wilcox, The GUSTO III Steering Committee, F. Van de Werf, The COBALT Investigators, et al. Thrombolytic Therapy for Myocardial Infarction N. Engl. J. Med., February 19, 1998; 338(8): 545 - 548. [Full Text]
|
|
|
|
|
|
C. P. Cannon, C. H. McCabe, S. Borzak, T. D. Henry, M. D. Tischler, H. S. Mueller, R. Feldman, S. T. Palmeri, K. Ault, S. A. Hamilton, et al. Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome : Results of the TIMI 12 Trial Circulation, February 3, 1998; 97(4): 340 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kearon, B. A. Baker, M. D. Adelman, A. Krulewitz, A. H. Goodall, C. Knight, M. Cohen, and P. W. Armstrong Low-Molecular-Weight Heparin versus Unfractionated Heparin for Unstable Coronary Disease N. Engl. J. Med., January 8, 1998; 338(2): 129 - 131. [Full Text]
|
|
|
|
|
|
R. H. White, H. Zhou, L. Woo, and D. Mungall Effect of Weight, Sex, Age, Clinical Diagnosis, and Thromboplastin Reagent on Steady-state Intravenous Heparin Requirements Arch Intern Med, November 24, 1997; 157(21): 2468 - 2472. [Abstract] [PDF]
|
|
|
|
|
|
The Global Use of Strategies to Open Occluded Coro A Comparison of Reteplase with Alteplase for Acute Myocardial Infarction N. Engl. J. Med., October 16, 1997; 337(16): 1118 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Schmaier, E. J. Topol, R. M. Califf, F. Van de Werf, and The GUSTO IIb Investigators Heparin versus Hirudin for Acute Coronary Syndromes N. Engl. J. Med., March 6, 1997; 336(10): 730 - 731. [Full Text]
|
|
|
|
|
|
B. S. Coller, D. Lang, and L. E. Scudder Rapid and Simple Platelet Function Assay to Assess Glycoprotein IIb/IIIa Receptor Blockade Circulation, February 18, 1997; 95(4): 860 - 867. [Abstract] [Full Text]
|
|
|
|
|
|
The Global Use of Strategies to Open Occluded Coro A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes N. Engl. J. Med., September 12, 1996; 335(11): 775 - 782. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||